Ongoing Clinical Trials for Adenosquamous Cell Lung Cancer Stage III
There are currently 3 clinical trials ongoing for adenosquamous cell lung cancer stage III, testing various treatment approaches including immunotherapy combined with chemotherapy, diagnostic testing methods, and personalized cell therapies. These trials are being conducted across several European countries including Germany, Hungary, Czechia, France, and Spain.
Clinical trial locations
- Czechia
- France
- Germany
- Hungary
- Spain
Study on Atezolizumab, Carboplatin, and Etoposide for Adults with Advanced Large-Cell Neuroendocrine Lung Cancer
This trial is testing a combination of immunotherapy and chemotherapy for adults with large-cell neuroendocrine lung cancer. The study uses atezolizumab, an immunotherapy drug that helps the immune system fight cancer, together with platinum-based chemotherapy drugs (carboplatin or cisplatin) and etoposide.
Main inclusion criteria: To participate, you must be at least 18 years old and have locally advanced or metastatic large-cell neuroendocrine carcinoma that cannot be cured with surgery. You should not have received previous systemic therapy, though prior curative treatment is allowed if the cancer returned at least 6 months after stopping treatment. You need to have an ECOG performance status of 0 to 2, meaning you can perform most daily activities. Your organ function must be adequate, with liver and kidney tests within acceptable ranges, and proper blood cell counts.
Main exclusion criteria: You cannot participate if you have received other cancer treatments within the last 4 weeks, have a history of severe allergic reactions to the study drugs, have active infections requiring treatment, are pregnant or breastfeeding, have participated in another clinical trial recently, or have untreated brain metastases. Those with autoimmune diseases or recent history of drug or alcohol abuse are also excluded.
Study focus: The trial aims to evaluate how well atezolizumab works when combined with standard chemotherapy in improving survival for patients with this type of lung cancer. Researchers will monitor how the cancer responds to treatment, track changes in tumor size, and assess any side effects experienced by participants.
Investigational drugs: Atezolizumab is an immunotherapy that helps your immune system recognize and attack cancer cells. The platinum-based drugs damage cancer cell DNA to stop their growth, while etoposide interferes with DNA inside cancer cells to prevent them from dividing.
Study on the Accuracy of OWL-EVO1 Test for Diagnosing Lung Cancer in Patients Eligible for Screening or with Suspicious CT Findings
This trial is evaluating a new diagnostic test called OWL-EVO1 Breath Biopsy that aims to help identify lung cancer more accurately. The test analyzes breath samples after administering a special solution through an intravenous infusion.
Main inclusion criteria: You must be between 45 and 85 years old and able to provide informed consent. Your body mass index must be between 16 and less than 40. You need to have had a CT scan of your chest within the last 6 months.
Main exclusion criteria: You cannot participate if you are not eligible for lung cancer screening based on low dose CT scans, if you don’t have suspicious findings on a CT scan, or if lung cancer is not part of your possible diagnosis based on your symptoms.
Study focus: The trial assesses how accurately the OWL-EVO1 test can differentiate between people who have lung cancer and those who don’t. Researchers will evaluate the safety and tolerability of the test and compare its results with other diagnostic methods.
Investigational approach: OWL-EVO1 is a diagnostic test that analyzes breath samples to detect specific markers that may indicate the presence of lung cancer. The goal is to improve diagnostic accuracy for individuals undergoing screening or those with suspicious CT scan findings.
Study on the Safety and Effects of ATL001 and Pembrolizumab in Adults with Advanced Non-Small Cell Lung Cancer
This trial explores a personalized cell therapy called ATL001 for advanced non-small cell lung cancer. The study examines how ATL001 works both alone and in combination with pembrolizumab, an already approved cancer treatment.
Main inclusion criteria: You must be between 18 and 75 years old with a life expectancy of at least 6 months. You need to have advanced non-small cell lung cancer that cannot be surgically removed or has spread to other parts of the body, with disease progression after standard treatments or inability to receive standard treatments. You must be in good general condition (ECOG 0-1) and have been previously treated with a PD-1/PD-L1 inhibitor. Adequate organ function is required, shown by specific blood test results. Female participants of childbearing potential must agree to use effective birth control during and after treatment.
Main exclusion criteria: You cannot participate if you have other types of cancer besides non-small cell lung cancer, cannot follow study procedures, have certain interfering medical conditions, are taking medications that conflict with the study, are pregnant or breastfeeding, have recently participated in another trial, or have a history of allergic reactions to the study drugs.
Study focus: The main goal is to assess the safety and tolerability of ATL001 as a treatment. The study will monitor how cancer responds over time and measure changes in tumor size and overall health outcomes, including how long patients live without cancer progression.
Investigational drugs: ATL001 is a cell therapy using specially designed T cells that recognize and attack cancer cells. Pembrolizumab is an immunotherapy that blocks a protein preventing the immune system from attacking cancer cells. The combination aims to see if the two treatments together can improve outcomes for advanced non-small cell lung cancer.
Summary
The three ongoing trials for adenosquamous cell lung cancer stage III represent different approaches to improving patient care. Two trials focus on treatment strategies using immunotherapy combined with either chemotherapy or personalized cell therapy, while one trial evaluates a novel diagnostic method. Germany appears most active in this research area, hosting two of the three trials. The studies span multiple European countries, with France, Spain, Hungary, and Czechia also participating.
A notable focus across the treatment trials is the use of immunotherapy drugs that help the immune system fight cancer cells. Atezolizumab and pembrolizumab both appear in these studies, either combined with traditional chemotherapy or with newer personalized approaches. The diagnostic trial offers a different angle by working to improve early and accurate detection through breath analysis, which could potentially lead to earlier intervention.
These trials are expected to continue through 2024 to 2029, with each offering different eligibility criteria and treatment approaches for patients at various stages of their cancer journey.
